Dr. Sandra Demaria

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy—one that boosts T cells and another that boosts dendritic cells—can control tumors in preclinical models of triple negative breast cancer, a cancer type that’s typically resistant to immunotherapy alone.

Awards, honors and achievements for the month of July. 

Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target...

Weill Cornell Medicine has been awarded a nearly $6.5 million, four-year grant from the Department of Defense as part of a multi-institutional Transformative Breast Cancer Consortium. 

Radiation therapy appears to increase or upregulate the expression of genes with mutations that induce an immune response to malignant cells, according to preclinical research by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Awards, honors, prizes and achievements for the month of January.

Combining radiation with an immune system-boosting therapy called ipilimumab led to regression of metastatic tumors not targeted by the radiation in lung cancer patients, according to results of an early clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

An enzyme implicated in autoimmune diseases and viral infections also regulates radiation therapy’s ability to trigger an immune response against cancer.